SIGA Technologies 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- SIGA completed its final product delivery under the BARDA 19C contract in the second quarter, fulfilling all product obligations under the agreement.
- SIGA signed a 5-year contract to supply oral TPOXX to Canada's Department of National Defense, valued at up to approximately $15 million, including firm commitments of about $9 million over the first 3 years and up to $6 million in options.
- The Canada contract is the department's second TPOXX contract; its first, awarded in April of 2020 for the purchase of up to approximately $14 million of TPOXX, was completed in 2025.
- For the 9 months ended September 30th, 2026, product-related revenues were approximately $42 million, including approximately $26 million of IV TPOXX deliveries to the U.S. Strategic National Stockpile and approximately $13 million of international sales to 2 international customers.
- SIGA recorded no product sales to customers in the third quarter; research and development revenues were approximately $7 million for the 9 months ended September 30th, 2026, including approximately $1 million in the third quarter.
- Pre-tax operating income for the 9 months ended September 30th, 2026 was approximately $2 million, while the third-quarter pre-tax operating loss was approximately $7 million.
- Net income for the 9 months ended September 30th, 2026 was approximately $6 million, or $0.09 per fully diluted share; the third-quarter net loss was approximately $3 million, or $0.04 per fully diluted share.
- At September 30th, 2026, SIGA had approximately $116 million in cash and no debt.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the SIGA business update call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations, and are subject to risks and uncertainties that could cause actual results to differ from forward-looking statements. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or changed circumstances after this call. For a discussion of factors that could cause results to differ, please see the company's filings with the Securities and Exchange Commission, including without limitation, the company's annual report on Form 10-K for the year ended December 31, 2025, and its subsequent reports on Form 10-Q and Form 8-K. With that, I will turn the call over to Diem Nguyen, Chief Executive Officer of SIGA.
Zem? Good afternoon, everyone, and thank you for joining today's call to review our business results.
I am joined by Dan Luckshire, our Chief Financial Officer, and we appreciate this opportunity to provide an update on our company. After the update, we will take your questions. Throughout 2026, SIGA has continued to execute on its core mission of working alongside governments to build and sustain long-term preparedness against potential biological threats, namely smallpox. We remain committed to positioning our smallpox therapeutic, TPOXX, for rapid, large-scale deployment should an outbreak occur. As a reminder, in the second quarter, we completed our final product delivery under the BARDA 19C contract, fulfilling all our product obligations under that agreement. We are proud of this partnership, proud of how we performed, and proud to have played an important role in strengthening the U.S. government's smallpox preparedness. We believe the case for preparedness against biological threats remains strong.
Geopolitical tensions and advances in technology, including AI, are reshaping the threat landscape. Mitigating these risks requires proactive, sustained government investment in medical countermeasures stockpiles. In an emergency, ready access to medical countermeasures is essential to protect both civilians and war fighters. At the same time, a compelling case for preparedness does not always translate into predictable procurement. As we discussed during our last call, the process to secure a new U.S. government contract has progressed more slowly than in the past, and the timing of an award remains uncertain. Even so, we remain confident that TPOXX has an important role in our nation's preparedness plans and that national security for medical countermeasures remain important to the U.S. government. Despite the lack of certainty as to timing and details, based on our discussions with key stakeholders, we continue to believe that a new procurement contract will be awarded.
Turning to our international business, I would like to share news of recent contract that advances our efforts to maintain a diverse revenue stream and customer base. Last month, we signed a contract to supply oral TPOXX to Canada's Department of National Defence, or CDND, over the next five years. This contract is valued up to approximately $15 million. It includes firm commitments about $9 million over the first three years, plus up to $6 million in options exercisable at CDND's discretion. This is CDND's second TPOXX contract. The first, awarded in April of 2020 for the purchase up to approximately $14 million of TPOXX, was completed in 2025. Canada continues to be one of the leaders in smallpox preparedness among our international customers, and we believe this award reflects that commitment. It also highlights another important point.
In a public health emergency, the men and women of the armed forces are often among the first called on to respond, so making sure they have access to smallpox antiviral is a key part of being prepared. Beyond this contract, we are continuing advanced discussions with other international customers, including one which we are in late-stage negotiations. We look forward to providing an update at the appropriate time. Moving to our development activities, I'd like to provide an update on our pediatric formulation and post-exposure prophylaxis, or PEP, programs. We continue to expect results from phase I study of our pediatric formulation by year end, and those results will inform next steps. If successful, this formulation, together with the oral and IV formulations, would extend TPOXX coverage across the full population, from infants to adults.
Children are among the most vulnerable in an outbreak, and an improved pediatric formulation will give governments a more complete solution for their stockpiles. On the PEP program, we continue to work closely with our partners at the Department of War, FDA, and CDC, all of whom remain highly engaged with this program. We recently met with the FDA to review the program, including the immunogenicity sample analysis the CDC plans to conduct. At that meeting, the FDA has asked us to perform additional validation and related laboratory work to help ensure the accuracy of results from the sample analysis. This work is important and requires time, and as a result, we now expect to file our supplemental NDA in 2028. While this delay is disappointing, it does not change our view on the relevance of this program.
In an outbreak, the ability to use TPOXX as a PEP for our military, first responders, and others exposed to smallpox virus can help save lives. Regarding our financial results, as I said in prior calls, our business is subject to inherent quarter-to-quarter variability, so our results are best viewed over a longer horizon than any single period. Over the first nine months of the year, product revenues totaled approximately $42 million, including sales to the U.S. government and customers in Asia-Pacific region and Europe. That breadth, together with the new CDND contract I talked about earlier, reflects the continued commitment of governments around the world to smallpox preparedness. Before I turn the call over to Dan, I want to recognize Dennis Hruby, our Chief Scientific Officer, who is retiring today after three decades with SIGA. When Dennis joined us in 1996, there was no approved treatment for smallpox.
Today, TPOXX is approved in the U.S., Canada, the European Union, the U.K., and Japan. It has been sold to more than 30 countries and is maintained in stockpiles around the world. Dennis's scientific leadership shaped the achievement at every step, from early-stage research through approval. On behalf of everyone at SIGA, I want to thank Dennis for his contributions to our company and to global health security. We're very pleased that he will continue to support us in an advisory role. In closing, SIGA has always been guided by its mission to ensure governments are prepared to protect their citizens from smallpox, and that mission is unchanged. While procurement processes are not predictable, we stand ready to work with our governments around the world, and we do so with a strong balance sheet, including $116 million in cash and no debt at the end of the quarter.
As I said at the start of the call, we believe the case for preparedness remains strong. Smallpox and other high-consequence threats are serious, and emerging technologies have the potential to lower barriers to creating or misusing biologic agents. With preparation, these threats can be mitigated, and TPOXX has a long history of helping governments meet smallpox threats. With that, I'll turn over to Dan to review our financial results in more detail.
Dan? Thanks, Zem. As noted earlier in the call, the company's product-related revenues are $42 million for the nine months ended September 30th, 2026, with most of the revenues being recorded in the second quarter, reflecting the variable rhythm of SIGA's business model.
Year-to-date product revenues include approximately $26 million of IV TPOXX deliveries to the U.S. Strategic National Stockpile and approximately $13 million of international sales to two international customers. For the third quarter, there are no product sales to customers. In addition to product-related revenues for the nine months ended September 30th, 2026, the company also has research and development revenues of approximately $7 million. Of this total, approximately $1 million of the research and development revenues were earned in the third quarter.
Pre-tax operating income for the nine months ended September 30th, 2026, which excludes interest income and taxes, is approximately $2 million. For the quarter, pre-tax operating loss is approximately $7 million. Net income for the nine months ended September 30th, 2026, is approximately $6 million. For the quarter, net loss is approximately $3 million. In turn, fully diluted income per share for the nine months ended September 30th, 2026, is $0.09 per share, while fully diluted loss per share for the quarter is $0.04 per share. The company continues to maintain a strong balance sheet. At September 30th, 2026, the company had a cash balance of approximately $116 million and no debt. This concludes the financial update. At this point, I will turn the call back to Zem.
Thank you, Dan. With that, we'd like to open the call for questions.
Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press the star key followed by the number 1 on your touchtone phone. You will hear a prompt that your hand has been raised. Should you wish to decline from the polling process, please press the star key followed by the number 2. One moment, please, while we assemble the queue. Your first question comes from Jyoti Prakash of Edison Group. Please go ahead. Hi, good evening.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
4 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
